REVTORPYK Drug Patent Profile
✉ Email this page to a colleague
When do Revtorpyk patents expire, and when can generic versions of Revtorpyk launch?
Revtorpyk is a drug marketed by Celcuity and is included in one NDA.
The generic ingredient in REVTORPYK is gedatolisib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the gedatolisib profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for REVTORPYK?
- What are the global sales for REVTORPYK?
- What is Average Wholesale Price for REVTORPYK?
Summary for REVTORPYK
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| What excipients (inactive ingredients) are in REVTORPYK? | REVTORPYK excipients list |
| DailyMed Link: | REVTORPYK at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for REVTORPYK
Generic Entry Date for REVTORPYK*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY NDA:
Dosage:
POWDER;INTRAVENOUS |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
US Patents and Regulatory Information for REVTORPYK
REVTORPYK is protected by zero US patents and one FDA Regulatory Exclusivity.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of REVTORPYK is ⤷ Start Trial.
This potential generic entry date is based on NEW CHEMICAL ENTITY.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celcuity | REVTORPYK | gedatolisib | POWDER;INTRAVENOUS | 219908-001 | Jul 14, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
